Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Salih Z Guclu"'
Autor:
Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss
Publikováno v:
Современная онкология, Vol 17, Iss 3, Pp 42-52 (2015)
Background. There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as
Externí odkaz:
https://doaj.org/article/d2707293f29543479eb0d50d65f683aa
Autor:
Shirish, Gadgeel, Glenwood, Goss, Jean-Charles, Soria, Enriqueta, Felip, Vassilis, Georgoulias, Shun, Lu, Manuel, Cobo, Konstantinos, Syrigos, Ki Hyeong, Lee, Erdem, Göker, Salih Z, Guclu, Dolores, Isla, Alessandro, Morabito, Nicholas, Dupuis, Claudia, Bühnemann, Nicole, Krämer, Flavio, Solca, Eva, Ehrnrooth, Andrea, Ardizzoni
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 109
Identification of biomarkers associated with clinical benefit may be crucial in establishing optimal treatment choice for patients with squamous cell carcinoma (SCC) of the lung after first-line chemotherapy. In this study, the ability of the VeriStr
Autor:
Kurt Krejcy, Zbigniew Kadziola, Younseup Kim, Salih Z Guclu, Chien-Te Li, Sedat Altug, M. M. Meshref, Shukui Qin, Magdalena Marek
Publikováno v:
Journal of Cancer
Background: This prospective observational study estimated the effect of prognostic factors, particularly continued smoking during therapy, on survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum. Further, p
Publikováno v:
Journal of Cancer, Vol 2, Iss 1, Pp 52-61 (2011)
Background: This prospective observational study estimated the effect of prognostic factors, particularly continued smoking during therapy, on survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum. Further, p